Highlights

  • Libbo’s 10 mg oral soluble film pilot study moved into preparation for dosing.
  • The company reported apixaban solubility above 50 mg/mL using its technology.
  • Ben Rohr was appointed chief executive effective 27 April 2026.

EVE Health Group Ltd (ASX:EVE) rose 7.69% to AUD 0.014, while its latest attached quarterly update covered clinical preparation and formulation testing. Libbo’s 10 mg oral soluble film pilot study moved into preparation for dosing. The company reported apixaban solubility above 50 mg/mL using its technology. Ben Rohr was appointed chief executive effective 27 April 2026.

Libbo Pilot Clinical Program

EVE Health Group reported progress during the June 2026 quarter on Libbo, a 10 mg vardenafil oral soluble film being developed for erectile dysfunction. The final protocol had been executed, and a contract research organisation and clinical site engaged. The planned pilot study is designed to compare Libbo with an approved vardenafil reference tablet in healthy male participants. The company said regulatory preparation includes comparative product testing and submission and review requirements. Pilot dosing was expected in Q4 2026, with initial data anticipated in early 2027. These dates represent the company expectations at the reporting date.

Apixaban Solubility Testing

EVE disclosed testing in which apixaban solubility exceeded 50 milligrams per millilitre using its proprietary formulation technology. It compared this with baseline aqueous solubility of approximately 0.6 milligrams per millilitre. Apixaban is the active ingredient in the anticoagulant Eliquis. EVE said the laboratory result formed part of a reformulation program for which a provisional patent application had been lodged. The filing did not describe the result as a clinical efficacy outcome, approved drug product or registration. The broader development program remained subject to further work and applicable regulatory requirements.

Management and Development Plans

Ben Rohr became chief executive officer effective 27 April 2026, following service as chief operating officer. EVE linked the appointment to its commercial and regulatory execution plans, including the integration of Nextract and the development of Dyspro and Libbo. The quarterly update said a satisfactory pilot result could inform a later pivotal bioequivalence study intended to support registration in the Australian Register of Therapeutic Goods. It also identified development programs relating to premature ejaculation, combination treatment and anticoagulation as part of its pharmaceutical reformulation pipeline.

Quarterly Cash Reporting

The Appendix 4C recorded AUD 266,000 of customer receipts in the June 2026 quarter and AUD 1.141 million for the 12 months ended 30 June 2026. The company disclosed AUD 83,000 in payments to related parties and their associates for the quarter, comprising AUD 72,000 in directors’ fees and superannuation and AUD 11,000 of office overhead payments. EVE described a capital-light, partner-led approach, assessing licensing and supply arrangements with partners offering manufacturing, regulatory and distribution capabilities. The clinical and commercial plans were framed as intended next steps.